CytoDyn Inc. (CYDY) Announces Engagement of Networ
Post# of 154757
Posted On: 12/22/2016 3:40:07 PM
CytoDyn Inc. (CYDY) Announces Engagement of NetworkNewsWire for Corporate Communications Solutions
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection and other diseases, announced this morning that it has engaged the expertise of NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility via social media and a rapidly expanding distribution network of well over 5,000 key syndication outlets.
“Maintaining strong communication with CytoDyn shareholders is highly important as we pursue regulatory approval of PRO 140, our leading monoclonal antibody for HIV infection,” Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated in this morning’s news release. “As we focus on our ongoing Phase 3 clinical trial with PRO 140, NNW will work behind the scenes and use its vast network to keep existing and potential investors up-to-date on our progress.”
As part of the Client-Partner relationship with CytoDyn, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“Though tremendously invaluable, communication strategies are an often overlooked aspect of business for many biotech and biopharma companies,” Sherri Franklin, director of Content Marketing for NNW, added in the release. “CytoDyn, however, is taking a proactive approach in making sure the investment community is aware of its progress. We look forward to working with this exciting company as it addresses a significant global concern and advances its clinical development of monoclonal antibodies for treatment of HIV infection.”
For more information, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection and other diseases, announced this morning that it has engaged the expertise of NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility via social media and a rapidly expanding distribution network of well over 5,000 key syndication outlets.
“Maintaining strong communication with CytoDyn shareholders is highly important as we pursue regulatory approval of PRO 140, our leading monoclonal antibody for HIV infection,” Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated in this morning’s news release. “As we focus on our ongoing Phase 3 clinical trial with PRO 140, NNW will work behind the scenes and use its vast network to keep existing and potential investors up-to-date on our progress.”
As part of the Client-Partner relationship with CytoDyn, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“Though tremendously invaluable, communication strategies are an often overlooked aspect of business for many biotech and biopharma companies,” Sherri Franklin, director of Content Marketing for NNW, added in the release. “CytoDyn, however, is taking a proactive approach in making sure the investment community is aware of its progress. We look forward to working with this exciting company as it addresses a significant global concern and advances its clinical development of monoclonal antibodies for treatment of HIV infection.”
For more information, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
(1)
(0)